Don't Think of Corlanor as a Replacement for Beta-Blockers for Heart Failure

June 2015

Corlanor (CORE-lah-nore, ivabradine) will be the first new drug approved for systolic heart failure in a decade.

It works by inhibiting the If or "funny" current in the sinoatrial node. This lowers heart rate...withOUT causing a drop in blood pressure.

Ivabradine prevents 1 in 25 patients from being hospitalized over 2 years...when ADDED to an ACEI or ARB, beta-blocker, and aldosterone antagonist. But it DOESN'T reduce overall mortality.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: PA includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote